Novo Nordisk A/S (NYSE:NVO) Trading Down 4.6% - Time to Sell?

Shares of Novo Nordisk A/S (NYSE:NVO - Get Free Report) traded down 4.6% during trading on Friday . The stock traded as low as $79.71 and last traded at $79.28. 5,157,028 shares changed hands during trading, a decline of 33% from the average session volume of 7,752,740 shares. The stock had previously closed at $83.07.

Analyst Ratings Changes

NVO has been the topic of a number of research analyst reports. Sanford C. Bernstein upgraded Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a report on Monday, January 6th. StockNews.com downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research report on Sunday, December 29th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Finally, BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating for the company in a research report on Monday, December 23rd. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Novo Nordisk A/S currently has a consensus rating of "Buy" and an average target price of $140.20.

Novo Nordisk A/S Price Performance

The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company's 50 day moving average is $97.76 and its 200-day moving average is $117.05. The stock has a market cap of $353.33 billion, a PE ratio of 25.48, a P/E/G ratio of 0.92 and a beta of 0.45.

Institutional Trading of Novo Nordisk A/S

Hedge funds and other institutional investors have recently made changes to their positions in the stock. International Assets Investment Management LLC raised its stake in Novo Nordisk A/S by 10,608.4% during the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC raised its position in shares of Novo Nordisk A/S by 257,816.0% during the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company's stock valued at $227,516,000 after acquiring an additional 1,593,303 shares in the last quarter. Mediolanum International Funds Ltd bought a new position in Novo Nordisk A/S during the third quarter worth $98,765,000. Marshall Wace LLP boosted its holdings in Novo Nordisk A/S by 34,472.1% in the second quarter. Marshall Wace LLP now owns 691,441 shares of the company's stock worth $98,696,000 after purchasing an additional 689,441 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Novo Nordisk A/S during the third quarter valued at $42,017,000. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.